Agilon Health, Inc.
AGL · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.12 | 0.00 | -0.33 | 0.18 |
| FCF Yield | -3.35% | -4.03% | -2.40% | 0.51% |
| EV / EBITDA | -2.78 | -8.61 | 252.74 | -6.59 |
| Quality | ||||
| ROIC | -33.65% | -23.28% | -4.16% | -18.89% |
| Gross Margin | 0.00% | -3.76% | 3.31% | -2.94% |
| Cash Conversion Ratio | 0.16 | 0.34 | -2.64 | -0.16 |
| Growth | ||||
| Revenue 3-Year CAGR | 14.22% | 18.93% | 24.42% | 30.80% |
| Free Cash Flow Growth | 62.71% | 10.58% | -1,172.82% | -39.96% |
| Safety | ||||
| Net Debt / EBITDA | 1.31 | 1.36 | -14.17 | 1.52 |
| Interest Coverage | 71.42 | -73.81 | -14.59 | -68.68 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 59.39 | -7.94 | -8.57 | -6.03 |